Swiss biotech Addex Therapeutics has completed its turnaround, just a matter of months after signing a collaboration agreement with Indivior PLC, by announcing a capital raise of CHF 40m ($41.8m) from financial institutions and family offices that will allow it to advance its portfolio of allosteric receptor modulators that include the Phase III-ready lead candidate, dipraglurant.
The financing is described as transformational by company CEO Tim Dyer, because as well as supporting the development of Addex's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?